Desescalation in Aromatase Inhibitors prescription for menopausal women with positive hormonal receptors breast cancers

The use of aromatase inhibitors (AI) is widely accepted in positive hormonal receptors breast cancers. However a significant proportion of patient complain for side effects leading to abandon the treatment. Since the effect of AI is mainly based on the decrease of serum estradiol, the question of dose adaptation in decreasing the dosage of IA while keeping its biological effect was raised.

Recent papers brought major contribution in this field and we present here an analysis of some of these recent data validating the reduction of AI prescription without harm for the patient.